1.
|
Phase: Phase IV, Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: GPOH-NB2004, EU-20661, NCT00410631
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ADO-MM-PAL8, NCT00226473
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: UKALL2003, NCT00222612
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 15
Sponsor: Other
Protocol IDs: GMALL05, NCT00199082
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 75
Sponsor: Other
Protocol IDs: CGC05MK1002, NCT00188149
|
|
8.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: Hemato INCAN 01/2007, NCT00429065
|
|
9.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NICHD
Protocol IDs: PPRU 10762, NCT00491946
|
|
10.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 and under
Sponsor: Other
Protocol IDs: LAL-BR/2001, NCT00526175
|
|
11.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and under
Sponsor: Other
Protocol IDs: LAL-AR-N-2005, NCT00526409
|
|
12.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and under
Sponsor: Other
Protocol IDs: 2007016, NCT00846703
|
|
13.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: LAL-AR/2003, NCT00853008
|
|
14.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and over
Sponsor: Other
Protocol IDs: PETHEMA LAL-07FRAIL, NCT01358201
|
|
15.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: RJ-2010-56, NCT01358253
|
|
16.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and over
Sponsor: Other
Protocol IDs: LAL-07OLD, NCT01366898
|
|
17.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: LAL Ph-2008, NCT01491763
|
|
18.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: LAL-AR/2011, NCT01540812
|
|
19.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-3, NCT01664975
|
|
20.
|
Phase: Phase III, Phase II
Type: Natural history/Epidemiology, Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 201010HBV, NCT01210287
|
|
21.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
|
|
22.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRO-1908, PRO1908TREND, NCT01277172
|
|
23.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI
Protocol IDs: COG-ANHL1131, ANHL1131, NCT01595048
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: NCI
Protocol IDs: SWOG-S9704, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: CDR0000068608, EURO-EWING-INTERGROUP-EE99, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, EU-20213, AEWS0331, NCT00020566
|
Mobile | Español
